Sylvamo SLVM Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $130M-3.7% | $135M+43.6% | $94M-16.8% | $113M-26.6% | $154M-24.9% | ||
| $26M+4.0% | $25M+4.2% | $24M-7.7% | $26M-3.7% | $27M0.0% | ||
| $1.73B+6.9% | $1.62B+3.6% | $1.56B+0.8% | $1.55B-1.0% | $1.57B-2.2% | ||
| $1.1B+2.0% | $1.08B+8.7% | $990M+1.3% | $977M-3.4% | $1.01B-4.9% | ||
| $1.06B+1.6% | $1.05B+0.2% | $1.05B+1.1% | $1.03B+5.8% | $977M+1,036% | ||
| $121M+6.1% | $114M-10.9% | $128M+1.6% | $126M+5.9% | $119M+7.2% | ||
| $76M+20.6% | $63M+21.2% | $52M-25.7% | $70M+6.1% | $66M-36.5% | ||
| $2.83B+2.6% | $2.76B+2.2% | $2.7B+1.3% | $2.67B-3.4% | $2.76B+6.1% | ||
| $407M+6.8% | $381M-0.5% | $383M+3.2% | $371M-3.9% | $386M+2.9% | ||
| $23M0.0% | $23M0.0% | $23M0.0% | $23M0.0% | $23M+4.5% | ||
| $758M+5.9% | $716M+9.6% | $653M+2.8% | $635M+3.1% | $616M-9.7% | ||
| $766M+0.4% | $763M-1.9% | $778M+1.4% | $767M-3.4% | $794M+1.5% | ||
| 200M0.0% | 200M0.0% | 200M0.0% | 200M0.0% | 200M0.0% | ||
| $2.49B-0.8% | $2.51B+0.6% | $2.5B+1.6% | $2.46B-0.1% | $2.46B+0.3% | ||
| $979M+1.3% | $966M-1.1% | $977M+1.9% | $959M+5.6% | $908M+7.2% | ||
| $2.83B+2.6% | $2.76B+2.2% | $2.7B+1.3% | $2.67B+1.5% | $2.63B+1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Sylvamo's total assets?
- Sylvamo (SLVM) holds $2.8B in total assets, up 2.6% year over year.
- How much debt does Sylvamo have?
- Sylvamo carries $861.0M in total debt against $979.0M of shareholders' equity, a debt-to-equity ratio of 0.88.
- How much cash does Sylvamo have?
- Sylvamo holds $130.0M in cash and equivalents.
- Can Sylvamo cover its short-term obligations?
- Its current ratio is 1.45 — current assets exceed current liabilities.
- Where does Sylvamo's balance sheet data come from?
- Every line is extracted from Sylvamo's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
